Long-Term Testosterone Therapy: Effects on Hypogonadal Men with Type 1 Diabetes
Farid Saad, DVM, PhD, Bayer Pharma AG explained to MD Magazine, at ENDO 2017 that he and his team conducted an effectiveness and safety study nearly 13 years ago on a long acting testosterone injection launched in Germany. They observed several patients visiting a urology office in the north of Germany with various complaints who were screened for testosterone therapy. If a patient was testosterone deficient, he was offered testosterone therapy, but he was required to complete at least 1 year of continuous treatment before entering the registry.
Saad learned that the men with type 1 diabetes did experience benefits of long-term testosterone therapy – they showed improvements in their underlying diseases. “We found, after many years of studying these patients, that these patients were continuously and progressively improving. For instance, the HP1C protein, which they measured routinely in the urology office, came down from a mean 7.9 to 5.9. They improved a lot,” Saad said.
Видео Long-Term Testosterone Therapy: Effects on Hypogonadal Men with Type 1 Diabetes канала HCPLive
Saad learned that the men with type 1 diabetes did experience benefits of long-term testosterone therapy – they showed improvements in their underlying diseases. “We found, after many years of studying these patients, that these patients were continuously and progressively improving. For instance, the HP1C protein, which they measured routinely in the urology office, came down from a mean 7.9 to 5.9. They improved a lot,” Saad said.
Видео Long-Term Testosterone Therapy: Effects on Hypogonadal Men with Type 1 Diabetes канала HCPLive
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Pediatric Status Epilepticus A Challenge For Physicians](https://i.ytimg.com/vi/wSoh95pUutA/default.jpg)
![Preventing Opportunistic Infections in HIV](https://i.ytimg.com/vi/VE7aC2h6BRc/default.jpg)
![The Future of Hepatic Encephalopathy Management](https://i.ytimg.com/vi/tnnuFlqgzQo/default.jpg)
![Approaching Therapy for IBS: Diet Modification](https://i.ytimg.com/vi/YU8lWHJR4Io/default.jpg)
![Pipeline Agents for the Treatment of Beta-Thalassemia](https://i.ytimg.com/vi/0Cg9TvqWNoc/default.jpg)
![Importance of Relapse Prevention in Schizophrenia](https://i.ytimg.com/vi/F3-3e0a8kug/default.jpg)
![Common Therapies in Lipodystrophy Treatment](https://i.ytimg.com/vi/W-Pdl2L20IM/default.jpg)
![Cognitive Assessment Tools in Alzheimer Disease](https://i.ytimg.com/vi/bfsv6ecMG0g/default.jpg)
![Andrea Dunaif, MD: PCOS Prevalence in Women with Type 2 Diabetes](https://i.ytimg.com/vi/shdfCwCw8YA/default.jpg)
![Optimal Treatment of Schizophrenia: Take-Home Messages](https://i.ytimg.com/vi/6tQB1Xq7VSc/default.jpg)
![Overview of COPD Medications](https://i.ytimg.com/vi/A65A4D8NRJ4/default.jpg)
![Benefits and Limitations of Nebulizers in COPD](https://i.ytimg.com/vi/xVTLlMhqvwA/default.jpg)
![Clostridium Difficile: The Role of Bezlotoxumab](https://i.ytimg.com/vi/5m897jd_30E/default.jpg)
![Switching HIV Therapy in Patients With Viral Suppression](https://i.ytimg.com/vi/Oci52y7dkfg/default.jpg)
![Understanding Transfusion for Beta-Thalassemia](https://i.ytimg.com/vi/Vqd0kRCLOJE/default.jpg)
![Duchenne Muscular Dystrophy and its Treatment Options](https://i.ytimg.com/vi/Q0ejNx2k3Xw/default.jpg)
![Preparing Patients for Insulin in Type 2 Diabetes](https://i.ytimg.com/vi/LGLhSS7qrcQ/default.jpg)
![Nutrition and Overall Health Status in Elderly Patients](https://i.ytimg.com/vi/_TdE8DC4OsQ/default.jpg)
![Clostridium Difficile: Avoiding High-Risk Antibiotics](https://i.ytimg.com/vi/hWzg3OzxRYc/default.jpg)
![Preston Klassen, MD: Potential of Etrasimod Outside of IBS/IBD](https://i.ytimg.com/vi/SUDi9NrpAEM/default.jpg)
![Bruce Neal on the CANVAS trial for diabetes](https://i.ytimg.com/vi/xVBJSr3HxIw/default.jpg)